Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1
复制标题
S-1 对晚期和复发性胃癌 (ARGC) 的长期控制
作者：
Haruhiko Cho;K. Konishi;A. Tsuburaya;O. Kobayashi;M. Sairenji;H. Motohashi;T. Imada
背景口服替加氟化合物S-1（TS-1®）被开发用于增强胃癌患者的抗肿瘤活性并减少胃肠道毒性。在日本，它对晚期和复发性胃癌（ARGC）取得了很高的有效率;然而，长期服用S-1的疗效和不良反应仍有待阐明。方法研究了69例接受S-1治疗的ARGC患者; 58例患者有可测量的病变，11例患者没有。结果总有效率为38%，其中完全缓解（CR）2例，部分缓解（PR）20例，稳定（SD）9例，进展（PD）23例。原发灶、淋巴结转移灶、腹膜转移灶和肝转移灶的有效率分别为40%、45%、38%和25%。当S-1作为二线化疗给药时（n = 25），缓解率为36%。在69名患者中，14名患者接受S-1治疗超过一年。这14例患者（包括3例疾病稳定患者）S-1给药后的中位生存时间（MST）为918天（范围：536 - 1107天）。14例长期应用S-1的患者均未发生3 ~ 4级毒副反应。结论S-1治疗原发性肝癌有效率高，与靶器官及既往化疗无关。S-1长期给药可能使ARGC患者获益，可提供长期疾病控制和可接受的毒性。
BackgroundAn oral tegafur compound, S-1 (TS-1®), was developed to potentiate antitumor activity and to reduce gastrointestinal toxicities for patients with gastric cancer. It has achieved a high response rate against advanced and recurrent gastric cancer (ARGC) in Japan; however, the efficacy and adverse reactions of longterm administration of S-1 remain to be elucidated.MethodsSixty-nine patients with ARGC treated with S-1 were studied; 58 patients had measurable lesions, while 11 patients did not. S-1 was orally administered at doses of between 40 and 60 mg/body twice daily for 28 days, followed by 14 days' rest, as one course.ResultsThe overall response rate was 38% (complete response [CR], 2/58; partial response [PR], 20/58; stable disease [SD], 9/58; progressive disease [PD] 23/58). Response rate by target organ was 40% for the primary lesion, 45% for lymph node metastasis, 38% for peritoneal metastasis, and 25% for liver metastasis. When S-1 was administered as second-line chemotherapy (n = 25), the response rate was 36%. Of the 69 patients, 14 received S-1 for more than a year. The median survival time (MST) after S-1 administration in these 14 patients, including 3 patients with stable disease, was 918 days (range, 536 to 1107 days). There were no grade 3 to 4 toxicities in these 14 patients receiving longterm therapy with S-1.ConclusionS-1 therapy was performed with a high response rate, irrespective of the target organ or the presence of prior chemotherapy. Longterm administration of S-1 may benefit patients with ARGC, providing prolonged disease control with acceptable toxicities.
影响因子：
45.3
作者：
KELSEN, D;ATIQ, OT;BRENNAN, M
通讯作者：
BRENNAN, M